View Financial HealthAimed Bio 배당 및 자사주 매입배당 기준 점검 0/6Aimed Bio 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-5.4%자사주 매입 수익률총 주주 수익률-5.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jun 16Now 21% overvaluedOver the last 90 days, the stock has fallen 53% to ₩28,600. The fair value is estimated to be ₩23,679, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 76% per annum over the same time period.분석 기사 • May 25Investors Shouldn't Be Too Comfortable With Aimed Bio's (KOSDAQ:0009K0) EarningsInvestors were disappointed with Aimed Bio Inc.'s ( KOSDAQ:0009K0 ) earnings, despite the strong profit numbers. We did...New Risk • May 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results.Buy Or Sell Opportunity • May 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to ₩33,300. The fair value is estimated to be ₩41,769, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.Buy Or Sell Opportunity • Apr 24Now 26% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₩50,200. The fair value is estimated to be ₩39,924, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.Buy Or Sell Opportunity • Apr 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ₩45,300. The fair value is estimated to be ₩57,241, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 79% over the last 3 years. Earnings per share has declined by 30%.공고 • Mar 13Aimed Bio Inc., Annual General Meeting, Mar 27, 2026Aimed Bio Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 9, jeongui-ro 8-gil, songpa-gu, seoul South KoreaBuy Or Sell Opportunity • Mar 04Now 31% undervaluedOver the last 90 days, the stock has risen 17% to ₩51,300. The fair value is estimated to be ₩73,923, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.Buy Or Sell Opportunity • Jan 28Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩57,200. The fair value is estimated to be ₩73,034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Inside Director Nam-Gu Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A0009K0 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A0009K0 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Aimed Bio 배당 수익률 vs 시장A0009K0의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A0009K0)n/a시장 하위 25% (KR)1.4%시장 상위 25% (KR)4.4%업계 평균 (Biotechs)0.5%분석가 예측 (A0009K0) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A0009K0 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A0009K0 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A0009K0 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A0009K0 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/28 08:20종가2026/07/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aimed Bio Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Keunhee SeoSamsung Securities Co. Ltd.
Buy Or Sell Opportunity • Jun 16Now 21% overvaluedOver the last 90 days, the stock has fallen 53% to ₩28,600. The fair value is estimated to be ₩23,679, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 76% per annum over the same time period.
분석 기사 • May 25Investors Shouldn't Be Too Comfortable With Aimed Bio's (KOSDAQ:0009K0) EarningsInvestors were disappointed with Aimed Bio Inc.'s ( KOSDAQ:0009K0 ) earnings, despite the strong profit numbers. We did...
New Risk • May 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results.
Buy Or Sell Opportunity • May 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to ₩33,300. The fair value is estimated to be ₩41,769, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.
Buy Or Sell Opportunity • Apr 24Now 26% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₩50,200. The fair value is estimated to be ₩39,924, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.
Buy Or Sell Opportunity • Apr 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ₩45,300. The fair value is estimated to be ₩57,241, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 79% over the last 3 years. Earnings per share has declined by 30%.
공고 • Mar 13Aimed Bio Inc., Annual General Meeting, Mar 27, 2026Aimed Bio Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 9, jeongui-ro 8-gil, songpa-gu, seoul South Korea
Buy Or Sell Opportunity • Mar 04Now 31% undervaluedOver the last 90 days, the stock has risen 17% to ₩51,300. The fair value is estimated to be ₩73,923, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.
Buy Or Sell Opportunity • Jan 28Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩57,200. The fair value is estimated to be ₩73,034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.
Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Inside Director Nam-Gu Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.